Our study verified the feasibility and potential superiority of multi-center 18F-FDG PET/CT-derived radiomics to identify EGFR mutation status and predict prognosis in lung adenocarcinoma, which may help to develop a non-invasive tool as a complementary to PET/CT for clinic. Here, EGFR is linked to lung adenocarcinoma.